XML 47 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Collaborative Agreements (Details) - USD ($)
1 Months Ended 6 Months Ended
Dec. 24, 2018
Sep. 30, 2017
Sep. 25, 2017
Jul. 24, 2017
May 26, 2017
Aug. 31, 2016
Jul. 27, 2016
Dec. 31, 2015
Jun. 30, 2019
Dec. 31, 2018
Dec. 31, 2017
Collaborative Agreements (Textual)                      
Outstanding balance                 $ 180,736 $ 59,477  
BHK Co-Development Agreement [Member]                      
Collaborative Agreements (Textual)                      
Description of payment settlement             Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment At the completion of first phase II clinical trial: $1 million, or 10% of total payment At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment        
Upfront payments             $ 1,000,000 $ 1,000,000      
Percentage of payments under co-development agreement             10.00% 10.00%      
Milestone payments to BioLite in cash           $ 31,649,000 $ 10,000,000        
Common stock newly issued, value           $ 1,000,000   $ 10,000,000      
Milestone payments royalty percentage           12.00%          
Collaborative Agreements, description               The Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of June 30, 2019 and 2018, the Company has not earned the royalty under the BHK Collaborative Agreements.    
Co-Dev Agreement [Member]                      
Collaborative Agreements (Textual)                      
Amount received from BriVision   $ 3,000,000     $ 3,000,000           $ 450,000
Percentage of payments under co-development agreement         50.00%            
Company cash payments   $ 3,000,000     $ 3,000,000            
Co-Dev agreement, description The Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene's Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.                    
BioFirst Stock Purchase Agreement [Member]                      
Collaborative Agreements (Textual)                      
Shares issued                 428,571    
Shares value                 $ 3,000,000    
Collaborative Arrangement [Member]                      
Collaborative Agreements (Textual)                      
Amount received from BriVision       $ 3,000,000              
Percentage of payments under co-development agreement       50.00%              
Common stock newly issued, value       $ 3,000,000              
Common stock newly issued, shares                 428,571    
Licensing rights     $ 3,000,000                
Accounts payable                 $ 15,000,000    
Research and development expense     $ 3,000,000